Loading...
Market
Highest revenue growth in oncology treatments by end of 2025?
2
Resolution / Starting Odds
Johnson & Johnson • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Financial reports and revenue data from major pharmaceutical companies
Story
Johnson & Johnson's RYBREVANT and LAZCLUZE Outperform Tagrisso, Promising Over One Year Survival Improvement Over Osimertinib
Jan 7, 2025, 01:11 PM
Johnson & Johnson announced that its lung cancer treatment, a combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), has shown a statistically significant and clinically meaningful improvement in overall survival compared to osimertinib. In a head-to-head study, this combination therapy outperformed AstraZeneca’s Tagrisso, which could potentially alter the standard of care for lung cancer, one of the most lethal tumor types. The company indicated that the median overall survival improvement is expected to exceed one year.
View original story
Similar markets
Europe • 25%
North America • 25%
Asia-Pacific • 25%
Other • 25%
Other • 25%
Breast Cancer • 25%
Gastrointestinal Cancer • 25%
Lung Cancer • 25%
Reni-cel leads • 33%
Casgevy leads • 33%
BEAM-101 leads • 33%
Latin America • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
$500 million to $1 billion • 25%
More than $2 billion • 25%
$1 billion to $2 billion • 25%
Less than $500 million • 25%
Top 20 • 25%
Below Top 20 • 25%
Top 10 • 25%
Top 5 • 25%
Cost-effectiveness • 25%
Efficacy • 25%
Patient Convenience • 25%
Combination Therapy Benefits • 25%
Other • 25%
Novo Nordisk • 25%
Sanofi • 25%
EMS • 25%
More than 15% increase • 25%
10% to 15% increase • 25%
5% to 10% increase • 25%
Less than 5% increase • 25%
United States • 25%
Other • 25%
China • 25%
European Union • 25%